Adverse drug reactions in patients with COVID-19 in Brazil: Analysis of spontaneous notifications of the Brazilian pharmacovigilance system
Cadernos de Saude Publica, ISSN: 1678-4464, Vol: 37, Issue: 1, Page: e00245820
2021
- 19Citations
- 16,710Usage
- 249Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
In March 2020, the World Health Organization announced the new COVID-19 pandemic, which represented a challenge for health services and professionals. An effective treatment against this disease has not yet been developed; as such, several drugs are used without evidence of efficacy, which in some cases may lead to unwanted events. This is a cross-sectional study with the objective of evaluating adverse drug reactions (ADRs) in patients with COVID-19, identified between March 1 and August 15, 2020, in Brazil, as well as assessing the factors associated with the emergence of severe reactions. To compare the proportions of samples related to the notifier, patient, drugs and adverse events, we used Fisher’s chi-square and exact nonparametric tests; and to compare the means of the data with normal distribution, we used the Student’s t-test and Mann-Whitney’s test. A multivariate logistic regression analysis was also performed, estimating the crude and adjusted odds ratio (OR) by the Stata software, version 10.0. A total of 631 ADRs were identified in 402 patients. The main drugs were hydroxychloroquine (59.5%), azithromycin (9.8%) and chloroquine (5.2%). The reactions manifested primarily in the cardiac system (38.8%), gastrointestinal system (14.4%), skin tissue (12.2%) and hepatic system (8.9%). Chloroquine (OR = 5.4; 95%CI: 1.9-15.6) and hydroxychloroquine (OR = 2.1; 95CI%: 1.2-3.6) were the only drugs associated with severe ADR. Our findings provide support for better practices in pharmacovigilance, contributing to effective and secure regulatory decision-making by the Brazilian Health Regulatory Agency, patients and society as a whole.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85100693410&origin=inward; http://dx.doi.org/10.1590/0102-311x00245820; http://www.ncbi.nlm.nih.gov/pubmed/33503163; http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2021000105013&tlng=pt; http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2021000105013&lng=en&tlng=en; http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0102-311X2021000105013&lng=en&tlng=en; http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2021000105013; http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0102-311X2021000105013; http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0102-311X2021000105013&lng=en&tlng=en; http://www.scielosp.org/scielo.php?script=sci_abstract&pid=S0102-311X2021000105013&lng=en&tlng=en; http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0102-311X2021000105013; http://www.scielosp.org/scielo.php?script=sci_abstract&pid=S0102-311X2021000105013; https://dx.doi.org/10.1590/0102-311x00245820; https://www.scielo.br/j/csp/a/DQHfJwbLrnjCQFZLsYtNZfN/?lang=pt
FapUNIFESP (SciELO)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know